In relation to reverse cholesterol transport, variants in the cholesteryl ester transfer protein (CETP) gene and treatment with a potent, target-specific CETP inhibitor for a sufficient duration, both result in reduced triglycerides, LDL-C and apoB, elevated HDL-C and apoA1 and reduced CHD risk.24 This evidence concerns the gene CETP and coronary artery disorder.